This year’s CME event in New York City is more case-based than ever and includes the latest in management of tricuspid valve disease too.
Two decades later, few centers offer advanced robotic approach to mitral valve repair
An underrecognized form of functional mitral regurgitation of atrial origin demands heightened attention due to higher risks of death and hospitalization for heart failure and lower intervention rates.
Three of our valve disease experts reflect on notable changes and developments related to mitral valve disease in the new guideline update.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Expanded use of minimally invasive mitral valve surgery will be the No. 2 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
It’s increasingly clear that there’s no good reason to delay surgical repair in patients with primary mitral valve disease and severe regurgitation. Two experts share perspectives about what that means in practice.
Experts advise on developments to look for in the transcatheter space when it comes to managing diseases of the mitral, tricuspid and pulmonary valves.
Nothing teaches as well as a good case. That’s the thinking behind the case-based design of this 1.5-day multidisciplinary exploration of mitral valve management.
The mitral valve poses anatomic challenges to transcatheter treatment that the aortic valve doesn’t. Here’s a glimpse into six ongoing studies designed to overcome them.
If the world-class faculty, spirited pro/con debates and unprecedently comprehensive agenda aren’t enough, then come for December sightseeing in New York.